Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

US Chem Labs

Has US Chem Labs received an FDA warning letter? Yes. FDA issued a warning letter dated February 7, 2024 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
February 7, 2024 (2024-02-07)
Issuing office
Center for Drug Evaluation and Research | CDER
Recipient type
Manufacturer / API
Products named
SemaglutideTirzepatideThymalin
Violation categories
Unapproved new drugMisbrandingCGMP / insanitary conditions

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA found Semaglutide, Tirzepatide, and Thymalin marketed as unapproved new drugs for human use despite 'research chemicals only' claims, and misbranded because labeling lacked adequate directions for use.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • unapproved new drugs
  • misbranded drugs

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.